FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales
The U.S. Food and Drug Administration (FDA) has issued a coordinated series of warning letters targeting companies marketing unapproved drug products online, signaling an intensified enforcement effort focused on internet-based health product claims and e-commerce distribution.
The latest enforcement action includes more than a dozen warning letters issued by FDA’s Center for Drug Evaluation and Research (CDER), with nearly all involving products marketed as unapproved new drugs or misbranded drugs.
While the individual products differ, the warning letters reveal several common themes that provide insight into FDA’s current enforcement priorities.
Intended Use Drives FDA Jurisdiction
Perhaps the strongest message throughout the warning letters is that FDA determines whether a product is a drug based on its intended use—not how a company chooses to market or categorize it.
In nearly every case, FDA cited website language, product labeling, testimonials, or promotional claims describing the treatment, prevention, mitigation, or cure of disease, or claims that the product affects the structure or function of the body.
Those claims transformed products marketed as herbal remedies, creams, gels, wipes, or wellness products into drugs under the Federal Food, Drug, and Cosmetic Act.
Without FDA approval, those products became unapproved new drugs.
Online Marketing Under Increased Scrutiny
Unlike many traditional FDA enforcement actions that begin with facility inspections, these warning letters were largely based on FDA reviews of company websites or products purchased online.
FDA investigators evaluated product listings, promotional language, and online labeling to determine intended use.
The initiative demonstrates FDA’s increasing reliance on digital surveillance and online marketplace monitoring as part of its compliance program.
Disease Claims Continue to Draw Enforcement
Many of the warning letters focused on products making claims involving serious medical conditions or sexual health disorders.
Examples included claims related to, erectile dysfunction, premature ejaculation, phimosis, balanitis, prostate disorders, and cancer treatment.
FDA has historically viewed these categories as particularly concerning because consumers may delay seeking appropriate medical care in favor of unapproved products.
In particular, cancer treatment claims remain among the agency’s highest enforcement priorities.
Marketplace Responsibility Expands
One of the most notable warning letters was issued to Amazon.com.
Rather than focusing solely on manufacturers or product marketers, FDA cited products that were purchased through Amazon’s website and distributed through the company’s Fulfillment by Amazon program.
The action suggests FDA expects large online marketplaces to play an active role in preventing unapproved drug products from reaching U.S. consumers.
As e-commerce continues to reshape healthcare product distribution, online platforms may face increasing regulatory expectations regarding third-party sellers and product listings.
A Consistent Compliance Message
Across the warning letters, FDA delivered a consistent regulatory message.
Companies are expected to evaluate all marketing claims, ensure product labeling complies with FDA requirements, understand that website content may establish intended use, investigate root causes of compliance failures, implement corrective and preventive actions (CAPA), and respond to FDA within 15 business days describing corrective actions.
The letters emphasize that enforcement extends beyond removing individual claims and requires firms to establish sustainable compliance systems.
MDP Perspective
Taken together, these warning letters represent more than isolated enforcement actions.
They illustrate FDA’s continued shift toward risk-based oversight of digital marketing and online commerce.
For manufacturers, distributors, importers, and online retailers, the message is clear: websites, product listings, social media content, and promotional materials receive the same regulatory scrutiny as traditional product labeling.
The initiative also reinforces one of the most fundamental concepts in FDA regulation: intended use determines product classification.
Companies that market products with disease treatment or structure/function claims should carefully evaluate whether those products require an approved drug application before entering the U.S. marketplace.
As digital commerce continues to expand, regulatory compliance can no longer focus solely on manufacturing and product quality. Marketing, e-commerce, labeling, and online communications have become essential components of an effective compliance program.
Links
FDA Warning Letter to Wild Arabic Herbs
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...
